Department of Medicine 3 – Rheumatology and Immunology

Early CCR6 expression on B cells modulates germinal centre kinetics and efficient antibody responses (2017) Reimer D, Lee AYS, Bannan J, Fromm P, Kara EE, Comerford I, Mccoll S, et al. Journal article "AND SUDDENLY YOU ARE A PERSON AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS!" DIFFERENT PERSPECTIVES OF INDIVIDUALS ON PREDICTIVE TESTING - RESULTS OF AN INTERNATIONAL QUALITATIVE INTERVIEW STUDY (2017) Mosor E, Stoffer M, Steiner G, Raza K, Stack RJ, Simons G, Falahee M, et al. Conference contribution STRUCTURAL DAMAGE PROGRESSION IN PATIENTS TREATED WITH METHOTREXATE, BARICITINIB MONOTHERAPY OR BARICITINIB plus METHOTREXATE BASED ON THEIR LEVEL OF CLINICAL RESPONSE IN THE PHASE 3 RA-BEGIN STUDY (2017) Van Der Heijde D, Durez P, Schett G, Naredo E, Ostergaard M, Meszaros G, Bello N, et al. Conference contribution SECUKINUMAB PROVIDES RAPID AND SUSTAINED PAIN RELIEF IN PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE FUTURE 2 STUDY (2017) Mcinnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL (2017) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SENSITIVE DETECTION OF DYNAMIC CHANGES OF BONE EROSIONS IN INFLAMMATORY ARTHRITIS BY MUSCULOSKELETAL ULTRASOUND: A COMPARATIVE ANALYSIS WITH HIGH-RESOLUTION PERIPHERAL QUANTITATVE COMPUTED TOMOGRAPHY (2017) Finzel S, Schett G, Kraus S, Voll R, Backhaus M Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL (2017) Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, et al. Conference contribution Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1 (2017) Rech J, Reinhardt M, Kavanaugh A, Geusens P, Mpofu S Conference contribution Tyrosine Kinase Inhibitor Nintedanib Reduces Development of Transplant Vasculopathy in a Murine Aortic Transplantation Model (2017) Gocht A, Ensminger SM, Distler J, Spriewald B, Ramsperger-Gleixner M, Weyand M, Heim C Conference contribution The importance of the NFAT5/TonEBP-Inediated osmotic stress response in B cells (2017) Rokvic L, Titze J, Schuh W, Jäck HM Conference contribution